Eligibility Module

Eligibility Module

The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.

Eligibility Module path is as follows:

Study -> Protocol Section -> Eligibility Module

Eligibility Module


Ignite Creation Date: 2025-12-24 @ 10:13 PM
Ignite Modification Date: 2025-12-24 @ 10:13 PM
NCT ID: NCT04483635
Eligibility Criteria: Inclusion Criteria: * are aged ≥18 and \<70 years old; * licenced to practice in Quebec; * working or scheduled to work over the next 16 weeks in a setting at high-risk of contact with COVID-19 infected individuals, particularly (but not only) those involved with aerosol generating medical procedures in hospitals and/or caring for patients in long-term care facilities; * working in high COVID incidence areas; * covered by the RAMQ for medical services and hospitalisations; * has a personal email or phone (to which to send every two weeks a reminder and questionnaire by email or text messages); * has a fixed address (to which to send the material) in the greater Montreal or surrounding areas. Exclusion Criteria: * vitamin D supplementation \>400 IU/day or \>12,000 IU/month in past 3 months; * intention to take \>400 IU per day during the study period; * suspected or previously documented COVID-19 infection; * history of nephrolithiasis, hypercalcemia, hyperphosphatemia, hyperparathyroidism, granulomatosis disease (e.g., tuberculosis, sarcoidosis), renal impairment/failure, or active cancer; * use of any of the following medications: lithium, teriparatide, or digoxin; * anticipated prolonged absence from work during the study period (i.e., pregnancy); * enrolment in a concurrent randomized trial; * has received a vaccine against COVID-19.
Healthy Volunteers: True
Sex: ALL
Minimum Age: 18 Years
Maximum Age: 69 Years
Study: NCT04483635
Study Brief:
Protocol Section: NCT04483635